(AMRN) Amarin Corporation plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AMRN) Amarin Corporation plc Complete Analysis Pack
See the Bigger Picture
This Amarin Corporation plc BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The page already shows a real preview of the actual report content, so you can check the format and depth before buying. Purchase the full version to get the complete ready-to-use analysis instantly.
Stars
No true Star asset
Amarin is still basically a one-molecule business at end-2025, centered on icosapent ethyl/Vazkepa. With U.S. branded sales hit by generic icosapent ethyl competition, no product clearly has both high growth and high market share, so the Star box is mostly empty. Management’s growth path now depends on ex-U.S. uptake and new label wins, not on a current Star asset.
2019 FDA REDUCE-IT label
The 2019 FDA REDUCE-IT label is Amarin Corporation plc’s strongest Star-like asset: it lifted Vascepa beyond triglyceride lowering into cardiovascular risk reduction for adults with elevated triglycerides and either established CVD or diabetes plus risk factors. REDUCE-IT cut major ischemic events by 25% in the trial, supporting premium pricing in a large prevention market. That broader label expands the addressable pool and keeps the U.S. growth story science-led.
2020 EMA Vazkepa approval
In December 2020, the European Medicines Agency approved Vazkepa, giving Amarin Corporation plc a second commercial runway beyond the U.S. Europe is still underpenetrated, so share can grow from a low base if reimbursement and physician adoption improve. That makes Vazkepa a classic Stars asset: high-growth, but still capital- and launch-heavy.
Mochida EPA collaboration
Mochida Pharmaceutical expands Amarin Corporation plc's EPA platform beyond the U.S. VASCEPA base, and partner-led work cuts Amarin Corporation plc's own sales and launch spend, which mattered after 2024 net sales fell to $175.5 million. If Mochida adds new indications, the model can scale with less capital, so this is the closest Star in the BCG grid.
- Expands EPA into new products
- Shifts launch burden to Mochida
- Limits reliance on U.S. revenue
- Best fit: near-Star growth asset
Specialty cardiovascular niche
Amarin Corporation plc’s specialty cardiovascular niche fits targeted cardiometabolic care, not mass-market volume. Selling through wholesale and specialty pharmacy channels supports focused prescriber access, and the segment still has room to grow if adoption improves. That makes it a high-opportunity BCG position, not a mature cash cow.
- Focused channel mix
- Prescriber growth drives upside
- High-opportunity niche
Amarin Lacks a 2025 Star as VASCEPA Faces Generic Pressure
Amarin Corporation plc has no true Star in 2025: VASCEPA/Vazkepa still has growth potential, but U.S. generic pressure cuts share and sales. The 2019 FDA cardiovascular label and 2020 EMA approval keep the asset science-led, yet growth now depends on ex-U.S. uptake and new indications. Mochida is the closest near-Star because it broadens the EPA platform with lower capital burden.
| Asset | Star fit | Key fact |
|---|---|---|
| VASCEPA/Vazkepa | Low | 25% REDUCE-IT event cut |
| Mochida | Near-Star | Partner-led expansion |
What is included in the product
Detailed Word Document
Amarin’s BCG Matrix maps Vascepa and pipeline assets to show where to invest, hold, or divest.
Editable Excel File
BCG matrix for Amarin Corporation plc, turning portfolio complexity into a quick, clear decision view
Reference Sources
Provides a traceable source trail for Amarin Corporation plc, boosting credibility and helping decision-makers verify assumptions fast.
Cash Cows
No durable cash cow
By end-2025, Amarin Corporation plc still does not have a durable Cash Cow. VASCEPA faces heavy U.S. generic pressure, so it no longer throws off the kind of high, steady cash seen in a true Cash Cow. Cash generation is thin and less predictable, and most of Amarin Corporation plc’s other assets still need funding, not cash returns.
Legacy U.S. Vascepa accounts
Legacy U.S. Vascepa accounts still throw off residual cash because repeat prescriptions and long-standing physician familiarity keep demand alive. The brand has been on the market since 2012, so Amarin Corporation plc has years of commercial trust built into the base, which lowers new selling effort. That said, the U.S. franchise is mature and not a fast grower, so it fits Cash Cows best as a harvest asset.
Wholesale and specialty pharmacy channels
Amarin Corporation plc’s wholesale and specialty pharmacy channels are a mature cash engine: they are already built, so incremental spend stays low while existing demand is converted into sales. In 2024, Amarin reported net product revenue of about $175 million, showing these channels can still pull cash from a shrinking but established base. That makes them infrastructure to milk, not build.
Prescriber familiarity with icosapent ethyl
Cardiologists and lipid-focused prescribers already know icosapent ethyl, backed by the REDUCE-IT trial and an FDA label for high-risk patients with elevated triglycerides. That lowers selling cost versus a new launch and helps Amarin keep more margin where share still exists.
In 2025, this matters more because the brand is mature, so repeat use depends on habit, guideline fit, and payer access, not heavy education. The molecule is reusable value, not a one-time growth story.
- Lower promotion cost
- Known by core prescribers
- Supports margin retention
- Mature, reusable asset
Clinical and regulatory dossier
Amarin Corporation plc’s VASCEPA has a deep clinical and regulatory dossier, anchored by REDUCE-IT, which enrolled 8,179 patients and cut major adverse cardiovascular events by 25% versus placebo. That evidence base, plus U.S. FDA approval since 2012 and the 2019 label expansion, lowers the need to re-prove the core story market by market. It fits a Cash Cow: mature, trusted, and able to keep monetizing with less new spend.
- REDUCE-IT: 8,179 patients
- 25% MACE reduction
- FDA-approved since 2012
- Label expanded in 2019
Amarin’s VASCEPA Is a Harvest Asset, Not a Growth Engine
Amarin Corporation plc has no true Cash Cow in 2025. VASCEPA still brings in some residual cash from legacy U.S. demand, but generic pressure keeps revenue and margins weak. The asset is mature and best viewed as a harvest business, not a growth engine.
| Metric | Value |
|---|---|
| 2024 net product revenue | ~$175M |
| REDUCE-IT patients | 8,179 |
| MACE reduction | 25% |
| FDA approval | 2012 |
Full Version Awaits
Amarin Corporation plc Reference Sources
The Amarin Corporation plc BCG Matrix preview you see here is the exact same document you’ll receive after purchase. It’s the full, final version—no watermarks, no demo content, and no hidden sections. Download it and use it right away for analysis, planning, or presentation.
Dogs
Post-generic U.S. VASCEPA
By end-2025, post-generic U.S. VASCEPA was the clearest Dog: generic icosapent ethyl cut the branded franchise to a low-share, low-growth niche. Pricing power and volumes stayed under pressure, so each sale brought in less than in peak years. Amarin still spent time and sales effort on a business that no longer scaled like a core growth asset.
Legacy U.S. commercialization overhead
Amarin Corporation plc’s U.S. sales and admin setup was built for a much bigger VASCEPA launch, but shrinking U.S. revenue leaves those fixed costs less covered and harder to defend. That raises cash-flow drag and makes the legacy commercial base a cash trap risk in BCG terms. With a thinner revenue stream, every extra dollar of SG&A hurts more than it helps.
Small market country launches
Lebanon and the UAE are real markets, but they are tiny next to the U.S. at about 335 million people and Germany at 84 million, so they do not yet provide scale. Together, Lebanon’s roughly 5.8 million people and the UAE’s 10.8 million still mean low volume. That keeps return on promotion and access work weak, which fits a low-share, low-growth Dogs position.
Single-molecule concentration risk
Amarin still lives on one active ingredient, icosapent ethyl, so pricing or payer cuts hit the whole business at once. That one-product setup leaves no mix cushion, no real portfolio synergies, and little room to offset share loss in a competitive omega-3 market. Structurally, that keeps the Dogs profile weak.
- One molecule drives the model.
- Access risk affects all revenue.
- No second asset to offset declines.
- Competitive pressure stays high.
Narrow triglyceride-only niche
Amarin Corporation plc’s triglyceride-only base is still a very small pool: the core severe hypertriglyceridemia label targets patients with triglycerides at or above 500 mg/dL, and that niche is far smaller than the broader cardiovascular market. Once a niche like this matures and generic icosapent ethyl pressure rises, growth usually stalls fast.
Amarin Corporation plc has already felt that squeeze, with U.S. exclusivity gone and generic competition since 2020. A narrow, now-mature segment makes it hard to rebuild scale, so revenue depends on a shrinking slice of demand rather than new categories.
- Small addressable patient pool
- Generic erosion cuts pricing power
- Limited path to fast growth
- Classic Dog profile
Amarin’s 2025 Dog: VASCEPA’s shrinking U.S. niche
Amarin Corporation plc’s Dogs are clear in 2025: U.S. VASCEPA is a low-share, low-growth asset after generic icosapent ethyl entered in 2020. The severe hypertriglyceridemia niche is small, and shrinking U.S. revenue leaves fixed SG&A undercovered.
| Dog factor | 2025 signal |
|---|---|
| U.S. generic entry | 2020 |
| Core label niche | TG ≥500 mg/dL |
| Scale outside U.S. | Small |
Question Marks
VAZKEPA Europe penetration
Europe is a growth market for VAZKEPA, but Amarin Corporation plc still has low share from a small base. The EU has about 447 million people and cardiovascular disease causes roughly 3.9 million deaths a year, so the upside is real. Still, uptake depends on reimbursement, physician education, and local access rules; if those improve, sales can scale fast, but if not, VAZKEPA stays a Question Mark.
Canada expansion
Canada, with about 41 million people, gives Amarin Corporation plc a second branded cardiovascular lane. The market is not saturated, so Vascepa can still win on reimbursement, physician use, and pharmacy access, but share is not locked in yet. That makes it a classic high-growth, low-share "Question Mark" with upside if adoption scales.
UAE and Lebanon rollout
UAE and Lebanon are question marks for Amarin Corporation plc: they add international reach, but the markets are too small to be cash cows. The upside is white-space growth, yet scale is still unproven and depends on access, reimbursement, and cardiologist adoption. In 2025, Amarin kept its global focus on expanding VASCEPA outside core markets, so these launches matter more for option value than near-term profit.
Mochida new indications
Mochida’s new indications from VASCEPA’s active ingredient could widen the treated pool beyond its current core use, but the idea is still early and unproven. In BCG terms, it fits a Question Mark: high upside if trials, approvals, and launch work, yet low current certainty. Amarin must fund development first; only then can this become a Star.
Next EPA-based products
Amarin Corporation plc’s next EPA-based products are a classic Question Mark: the platform could reduce reliance on one branded drug and open new revenue streams, but it still carries clear execution, regulatory, and launch risk. With VASCEPA/Vazkepa still the core EPA asset, any follow-on wins could matter a lot if they reach market. The upside is real, but the path is not.
- Can diversify beyond one product
- New revenue streams are possible
- Regulatory risk stays high
- Commercialization risk is still real
Amarin’s Growth Bets: Big Market, Low Share, High Risk
Amarin Corporation plc’s Question Marks are VAZKEPA/Vascepa expansion bets with high growth and low share. Europe has about 447 million people and 3.9 million cardiovascular deaths a year, while Canada has about 41 million people; both can scale, but reimbursement and physician uptake still decide wins. UAE, Lebanon, and next EPA programs add option value, yet they remain early and risky.
| Question Mark | 2025 signal |
|---|---|
| Europe | Large market, low share |
| Canada | Growth lane, access-led |
| UAE/Lebanon | Small, option value only |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.